Over a 4-year study period, the price for 30 tablets of preexposure prophylaxis (PrEP) medication increased more than 20%, potentially keeping the medication out of the hands of those most at risk for potentially contracting HIV.
Between 2014 and 2018, the average price for 30 tablets of tenofovir disoproxil fumarate with emtricitabine (TDF-FTC) for preexposure prophylaxis (PrEP) increased more than 20%, potentially keeping the medication out of the hands of those most at risk for potentially contracting HIV, according to study results in Annals of Internal Medicine.
“The cost of TDF-FTC is estimated to be the largest driver of the cost of providing PrEP care,” the study authors noted. “Further, the cost of TDF-FTC has increased annually above the rate of inflation.”
Despite most of the cost of PrEP being covered by insurance companies, public insurance (Medicaid, Medicare), and financial assistance programs, uptake remains suboptimal. Therefore, using the IQVIA Real World Data Longitudinal Prescriptions database, the authors investigated third-party and out-of-pocket (OOP) costs for PrEP between 2014 and 2018. Data for close to 92% of retail and 60% to 86% of mail-order prescriptions are captured by IQVIA.
Between 2014 and 2018, 90,994,854 TDF-FTC tablets were dispensed, for 2,649,900 total paid PrEP prescriptions. These numbers grew every year of the study, as did patients receiving PrEP:
Data on cost for the same period for 30 tablets of TDF-FTC were also available:
In addition, mean OOP payments for 30 tablets differed in several demographic areas by the end of the study period in 2018:
Because prescription data available varied—from 99% of prescriptions in 2014-2015 to just 65% for 2016-2018—“to generate estimates of TDF–FTC payments across the health care system, the total payments for prescriptions with missing payment data were multiply imputed using a generalized linear model.” This analysis revealed:
Despite these costs and expenditures seeming high, the authors noted that according to the CDC for 2018, just 18.1% of patients requiring PrEP had coverage for it and almost half did not continue the medication for the entire year. In addition, for the study period, OOP payments outpaced third-party payments.
An editorial on the study results called this conundrum a “cost noose,” because only a minority of those who can benefit from PrEP can seemingly afford it. These authors hope that increased market competition will drive the price down: generic TDF-FTC is expected to enter the market over the next few months, and long-acting cabotegravir is hoping for eventual approval (the FDA issued a complete response letter to developer Viiv Healthcare last December, but not for safety issues). And because Gilead Sciences also makes the other PrEP medication approved for use in the United States, tenofovir alafenamide with emtricitabine, but is unwilling to reduce the prices of either formulation, “price reductions are thus likely only through future market competition,” they noted.
“The high cost of PrEP does not diminish its central role in the Ending the HIV Epidemic initiative,” the authors of the present study concluded. “Rather, it should promote action around ways to lower PrEP costs to the health care system to prevent coverage denials, eliminate prior authorization requirements, and increase access.”
Furukawa NW, Zhu W, Huang Y-LA, Shrestha RK, Hoover KW. National trends in drug payments for HIV preexposure prophylaxis in the United States, 2014 to 2018. Ann Intern Med. Published online September 8, 2020. doi:10.7326/M20-0786